Talis Biomedical Corporation Stock News

TLIS earnings call for the period ending December 31, 2021.

TLIS earnings call for the period ending December 31, 2021.

Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q4 2021 Results - Earnings Call Transcript

Talis Biomedical press release (TLIS): Q4 Net loss of $28.65M.Revenue of $0.86M (+273.9% Y/Y) misses by $0.47M.

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Final Deadline Alert: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm

Deadline Tomorrow Alert: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Fir

A Deadline is coming up on March 8, 2021 in the lawsuit for certain investors in Talis Biomedical Corporation (NASDAQ:TLIS). San Diego, CA -- ( SBWIRE ) -- 03/07/2022 -- The Shareholders Foundation announced that a deadline is coming up on March 8, 2021 in the lawsuit filed for certain investors of Talis Biomedical Corporation (NASDAQ: TLIS) Investors who purchased shares of Talis Biomedical Corporation (NASDAQ: TLIS) have certain options and there are strict and short deadlines running. Deadline: March 8, 2021. Talis Biomedical Corporation (NASDAQ: TLIS) stockholders should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The plaintiff alleges on behalf of purchasers of Talis Biomedical Corporation (NASDAQ: TLIS) common shares, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the Defendants failed to disclose to investors: (1) that the comparator assay in the primary study lacked sufficient sensitivity to support Talis''s EUA application for Talis One COVID-19 test; (2) that, as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test; (3) that, as a result, the Company''s commercialization timeline would be significantly delayed; and (4) that, as a result of the foregoing, Defendants'' positive statements about the Company''s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

NEW YORK, March 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s February 2021 initial public offering (“IPO” or the “Offering”), of the important March 8, 2022 lead plaintiff deadline.

SAN FRANCISCO, March 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS ) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants'' representations during Talis'' Feb. 2021 initial public offering. Class Period: Feb. 8, 2021 – Jan. 7, 2022 Lead Plaintiff Deadline: Mar. 8, 2022 Visit: www.hbsslaw.com/investor-fraud/TLIS Contact An Attorney Now: [email protected] 844-916-0895 Talis Biomedical Corporation (TLIS) Securities Class Action: Talis touted in its IPO documents that it submitted an application for emergency use authorization ("EUA") to the FDA for its Talis One COVID-19 test in Jan. 2021. The company said it assessed the performance of the Talis One platform comparing nasal specimens with tests conducted in a central lab using the Center for Disease Control and Prevention assay, the test data used to assess the test exactly matched central lab results, and this suggested clinical sensitivity …

SAN FRANCISCO, March 06, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Talis Biomedical Corporation (NASDAQ: TLIS) investors with significant losses to submit your losses now . A securities class action has been filed concerning defendants’ representations during Talis’ Feb. 2021 initial public offering.

Deadline Tuesday Notice: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Fir

Deadline Tuesday Alert: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)---- $TLIS--Securities Fraud Class Action Filed Against Talis Biomedical Corporation with Lead Plaintiff Deadline Approaching

Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the F